On December 17, 2010, Anvisa issued Regulation No. 55/2010, establishing the requirements for granting marketing approval to new biological products and biological products.
Despite the fact that the Brazilian legislation does not use the terms ‘biosimilars’ or ‘biogenerics’, the concept of registration by reference to third parties’ data packages is fully supported by the regulation. This raises concerns regarding Brazil’s widespread lack of enforcement of data package exclusivity (DPE).
A request for marketing approval of biological products (not new) can be made in two different ways: individual development and development by comparability. When choosing individual development, the applicant must submit a technical report, non-clinical studies and clinical studies performed on the product. However, the scope of the non-clinical studies can be reduced and the phase I and II studies can be exempted.
Phase III studies are mandatory (with exceptions) and must be comparatives of ‘non-inferiority’, ‘equivalence’ or ‘superiority’ to the new biological product. Otherwise, when using the development by comparability standard, it is necessary to submit a comparative dossier containing non-clinical and clinical studies used to demonstrate comparability between the biological product to be approved and the biological product used as a comparator.
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email James Lynn on email@example.com.
Brazil, biosimilar medicines